scholarly journals CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia

2022 ◽  
Vol 11 ◽  
Author(s):  
Oren Pasvolsky ◽  
May Daher ◽  
Gheath Alatrash ◽  
David Marin ◽  
Naval Daver ◽  
...  

Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet need. Building on growing knowledge of the interactions between leukemic cells and their bone marrow microenvironment, strategies to battle AML by immunotherapy are under investigation. In the current review we describe the advances in immunotherapy for AML, with a focus on chimeric antigen receptor (CAR) T cell therapy. CARs constitute powerful immunologic modalities, with proven clinical success in B-Cell malignancies. We discuss the challenges and possible solutions for CAR T cell therapy development in AML, and examine the path currently being paved by preclinical and clinical efforts, from autologous to allogeneic products.

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 439
Author(s):  
M. Fontaine ◽  
E. Breman ◽  
B. Demoulin ◽  
S. Bornschein ◽  
J. Bolsée ◽  
...  

2019 ◽  
Vol 8 (2) ◽  
pp. 200 ◽  
Author(s):  
Susanne Hofmann ◽  
Maria-Luisa Schubert ◽  
Lei Wang ◽  
Bailin He ◽  
Brigitte Neuber ◽  
...  

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients.


2019 ◽  
Vol 25 (3) ◽  
pp. S167-S168 ◽  
Author(s):  
Pinar Ataca Atilla ◽  
Erden Atilla ◽  
Haruko Tashiro ◽  
Madhuwanti Srinivasan ◽  
Diogo Gomes Silva ◽  
...  

2020 ◽  
Vol 10 ◽  
Author(s):  
Hui Zhang ◽  
Wen-Ting Gan ◽  
Wen-Ge Hao ◽  
Peng-Fei Wang ◽  
Zhuo-Yan Li ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xiaolei Sun ◽  
Guoling Wang ◽  
Shiyu Zuo ◽  
Qing Niu ◽  
Xiaoli Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document